Oncology Venture A/S announced the appointments of a new CEO and a new CFO. Steve Carchedi appointed as new Chief Executive Officer. The Board of Directors has appointed Steve Carchedi as new CEO of Oncology Venture.

He will take up the position on 15 September 2019, succeeding Dr. Peter Buhl Jensen, who will move to a role as Chairman of Oncology Venture's Medical & Scientific Advisory Board. Steve Carchedi has more than 30 years of experience in the biopharmaceutical industry, including CEO positions at Nasdaq-listed companies. He holds an MBA and B. Sc.

in Marketing and was recently CEO and Board Director of Apexian Pharmaceuticals, a private US company focused on oncology. He also serves on the Board of Directors of Sunesis Pharmaceuticals and BioNumerik Pharmaceuticals. Mr. Carchedi was responsible for Johnson & Johnson's global launch of Velcade ® (bortezomib) ­ an oncology drug with peak sales exceeding USD 500 million.

He has also successfully managed the clinical development operations of three early-stage oncology companies. Henrik Moltke has been appointed new CFO of Oncology Venture. He will take up the position on 1 October 2019, succeeding Niels Laursen.

Henrik Moltke, M.Sc. (Econ), is a senior executive with more than 30 years of experience as CFO and Senior Vice President within the life science industry. The primary focus in his career has been in financial transactions, IPO activities, investor relations and corporate communication at companies like Scandinavian Micro Biodevices ApS, Astion Pharma A/S, NeuroSearch A/S, Novo A/S, and Ferrosan A/S. He also has broad experience from board positions in several listed and private companies, and is currently serving on the Board of Directors of Werner Richters og Hustrus Legat, Initiator Pharma A/S and Hartmanns A/S.